bluebird reports updated LentiGlobin data

bluebird bio Inc. (NASDAQ:BLUE) said treatment with the company's LentiGlobin BB305 gene therapy using a modified protocol led to improved vector copy numbers (VCNs) in 2 patients receiving the therapy in the open-label, U.S. Phase I HGB-206 trial to treat severe sickle cell disease.

LentiGlobin BB305 comprises autologous CD34+ stem cells transduced ex vivo with a lentiviral vector delivering the human beta globin gene. The announcement came ahead of the company's planned presentations next month at the American Society of Hematology meeting in Atlanta...